March 13 (Reuters) – The collapse of Silicon Valley Lender (SIVB.O) will depart early-phase biotechnology businesses with a funding void, traders and analysts reported on Monday, but much larger, publicly-traded drug companies ought to escape unscathed. About 50{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} of U.S. biotech organizations, developing medicine for every thing from most cancers […]